Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) insider Brian Baranick sold 1,350 shares of Exact Sciences stock in a transaction on Monday, August 7th. The shares were sold at an average price of $85.04, for a total transaction of $114,804.00. Following the sale, the insider now directly owns 8,871 shares of the company’s stock, valued at approximately $754,389.84. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Exact Sciences Stock Down 0.7 %
NASDAQ:EXAS opened at $84.50 on Wednesday. Exact Sciences Co. has a 12 month low of $29.27 and a 12 month high of $100.77. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.14 and a current ratio of 2.41. The company’s 50-day moving average price is $92.33 and its two-hundred day moving average price is $76.46.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last released its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.05. The firm had revenue of $622.10 million for the quarter, compared to analyst estimates of $601.14 million. Exact Sciences had a negative net margin of 18.76% and a negative return on equity of 14.08%. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.94) earnings per share. Equities analysts predict that Exact Sciences Co. will post -1.94 EPS for the current year.
Hedge Funds Weigh In On Exact Sciences
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. Jefferies Financial Group lifted their price objective on shares of Exact Sciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Credit Suisse Group lifted their price objective on shares of Exact Sciences from $75.00 to $90.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. The Goldman Sachs Group lifted their price objective on shares of Exact Sciences from $85.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, July 21st. Citigroup lifted their price objective on shares of Exact Sciences from $100.00 to $130.00 in a research note on Thursday, June 22nd. Finally, Robert W. Baird lifted their target price on shares of Exact Sciences from $99.00 to $121.00 and gave the stock an “outperform” rating in a report on Wednesday, August 2nd. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.12.
Read Our Latest Stock Report on EXAS
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
- Five stocks we like better than Exact Sciences
- What is the S&P/TSX Index?
- AI is Turning Things Up for Upwork
- How to Calculate Stock Profit
- 2 Tech Stocks to Buy and One to Avoid in August
- How to Invest in Apparel Stocks
- 5 Best Fintech Stocks to Buy Now
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
